Top of this page
Skip navigation, go straight to the content
Our Science
•
Pipeline
R&D pipeline
The UCB pipeline delivers:
- a promising portfolio targeting severe diseases and addressing unmet medical needs
- focus on neurological and immunological diseases
- more convenient and effective treatments for patients and specialists.
| Indications | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|
| bimekizumab (IL17AF) | psoriasis |  | ||||
| psoriatic arthritis |  | |||||
| axial spondyloarthritis | | |||||
| hidradenitis suppurativa | | |||||
| zilucoplan (C5) | myasthenia gravis | | ||||
| immune-mediated necrotizing myopathy (IMNM) |  | |||||
| rozanolixizumab (FcRn) | myasthenia gravis | | ||||
| immune thrombocytopenia | | |||||
| chronic inflammatory demyelinating polyneuropathy (CIDP) | | |||||
| dapirolizumab pegol (CD40L) | systemic lupus erythematosus1 | | ||||
| Staccato® alprazolam | active epileptic seizure |  | ||||
| UCB0107 | progressive supranuclear palsy (PSP) |  | ||||
| 4 Projects |  | |||||
1 In partnership with Biogen |